Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008

被引：1

作者：

Lavie, David ^{[1
]}

Timmerman, John ^{[2
]}

Garcia-Sanz, Ramon ^{[3
]}

Kim, Won Seog ^{[4
]}

Kim, Tae Min ^{[5
]}

Avigdor, Abraham ^{[6
]}

Dierickx, Daan ^{[7
]}

Jagadeesh, Deepa ^{[8
]}

Molin, Daniel L. ^{[9
]}

Ozcan, Muhit ^{[10
]}

Sevindik, Omur Gokmen ^{[11
]}

Saeed, Hayder ^{[12
]}

Sidi, Yulia ^{[13
]}

Pillai, Pallavi ^{[13
]}

Marinello, Patricia ^{[13
]}

Herrera, Alex F. ^{[14
]}

机构：

[1] Hadassah Med Ctr, Jerusalem, Israel

[2] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA

[3] Univ Hosp Salamanca, Salamanca, Spain

[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[5] Seoul Natl Univ Hosp, Seoul, South Korea

[6] Sheba Med Ctr Tel HaShomer, Ramat Gan, Israel

[7] Univ Hosp Leuven, Leuven, Belgium

[8] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA

[9] Uppsala Univ, Uppsala, Sweden

[10] Ankara Univ, Sch Med, Hematol Dept, Ankara, Turkiye

[11] Istanbul Medipol Univ, Int Sch Med, Istanbul, Turkiye

[12] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[13] Merck & Co Inc, Rahway, NJ 07065 USA

[14] City Hope Natl Med Ctr, Duarte, CA USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-182119

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[41] Safety and Efficacy of Vibostolimab and Pembrolizumab in Patients with Relapsed or Refractory Hematologic Malignancies: A Multicohort, Open-Label, Phase 2 Study
Yusuf, Rushdia
Jemielita, Thomas
Marinello, Patricia
BLOOD, 2021, 138
[42] Safety and efficacy of decitabine-primed anti-PD-1 (SHR-1210) treatment in patients with relapsed/refractory classical Hodgkin lymphoma.
Wang, Chunmeng
Liu, Yang
Nie, Jing
Shen, Lianjun
Yang, Qingming
Han, Wei Dong
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[43] KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM).
Shah, Jatin J.
Jagannath, Sundar
Mateos, Maria-Victoria
Palumbo, Antonio
Kher, Uma
Marinello, Patricia Maria
San Miguel, Jesus
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[44] Efficacy of Chemotherapy or Chemo-Anti-PD-1 Combination after Unsatisfactory Response of Anti-PD-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Retrospective Series from Lysa Centers
Rossi, Cedric
Gilhodes, Julia
Maerevoet, Marie
Herbaux, Charles
Brice, Pauline
Garciaz, Sylvain
Borel, Cecile
Ysebaert, Loic
Oberic, Lucie
Lazarovici, Julien
Deau-Fisher, Benedicte
Dupuis, Jehan
Chauchet, Adrien
Abraham, Julie
Bijou, Fontanet
Stamatoullas-Bastard, Aspasia
Malfuson, Jean Valere
Golfier, Camille
Laurent, Camille
Kanoun, Salim
Filleron, Thomas
Casasnovas, Rene-Olivier
Ghesquieres, Herve
BLOOD, 2017, 130
[45] Gls-010, a Novel Anti-PD-1 Mab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Preliminary Impressive Results of a Phase II Clinical Trial
Song, Yuqin
Zhu, Jun
Lin, Ningjing
Zhang, Mingzhi
Bai, Hai
Liu, Hui
Cui, Jie
Ke, Xiaoyan
Zhang, Huilai
Liu, Lihong
Yan, Dongmei
Jiang, Yongsheng
Zang, Aimin
Qi, Junyuan
Wang, Li
Liu, Zhuogang
Xu, Bing
Zhang, Ying
Zhang, Zhihui
Meng, Haijin
BLOOD, 2020, 136
[46] Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Hutchings, Martin
Mous, Rogier
Clausen, Michael Roost
Johnson, Peter
Linton, Kim M.
Chamuleau, Martine E. D.
Lewis, David John
Balari, Anna Sureda
Cunningham, David
Oliveri, Roberto S.
Elliott, Brian
DeMarco, Dena
Azaryan, Ada
Chiu, Christopher
Li, Tommy
Chen, Kuo-mei
Ahmadi, Tahamtan
Lugtenburg, Pieternella J.
LANCET, 2021, 398 (10306): : 1157 - 1169
[47] An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma
von Tresckow, Bastian
Morschhauser, Franck
Ribrag, Vincent
Topp, Max S.
Chien, Caly
Seetharam, Shobha
Aquino, Regina
Kotoulek, Sonja
de Boer, Carla J.
Engert, Andreas
CLINICAL CANCER RESEARCH, 2015, 21 (08) : 1843 - 1850
[48] Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
Annunziata, Christina M.
Kohn, Elise C.
LoRusso, Patricia
Houston, Nicole D.
Coleman, Robert L.
Buzoianu, Manuela
Robbie, Gabriel
Lechleider, Robert
INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 77 - 84
[49] Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
Christina M. Annunziata
Elise C. Kohn
Patricia LoRusso
Nicole D. Houston
Robert L. Coleman
Manuela Buzoianu
Gabriel Robbie
Robert Lechleider
Investigational New Drugs, 2013, 31 : 77 - 84
[50] A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
Bartlett, Nancy L.
Herrera, Alex F.
Domingo-Domenech, Eva
Mehta, Amitkumar
Forero-Torres, Andres
Garcia-Sanz, Ramon
Armand, Philippe
Devata, Sumana
Izquierdo, Antonia Rodriguez
Lossos, Izidore S.
Reeder, Craig
Sher, Taimur
Chen, Robert
Schwarz, Sylvia E.
Alland, Leila
Strassz, Andras
Prier, Kim
Choe-Juliak, Cassandra
Ansell, Stephen M.
BLOOD, 2020, 136 (21) : 2401 - 2409

← 1 2 3 4 5 →